A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer

LESSONS LEARNED. The combination of everolimus and low‐dose prednisone administered daily was hypothesized to prevent noninfectious pneumonitis (NIP) and mucositis, two common adverse events related to everolimus. Although mucositis was detected in only one case, all‐grade NIP occurred in four of ei...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Lolli, Cristian, Gallà, Valentina, Schepisi, Giuseppe, Barone, Domenico, Burgio, Salvatore Luca, Maugeri, Antonio, Vertogen, Bernadette, Amadori, Dino, De Giorgi, Ugo
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5507652/
https://ncbi.nlm.nih.gov/pubmed/28546463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0154
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados